Revolutionizing Hyperbaric Oxygen Therapy: BARIKS Unveils Game-Changing Portable Chambers

BARIKS, an Israeli pioneer in Hyperbaric Oxygen Therapy (HBOT), introduces a game-changing innovation: a patented, portable, foldable hyperbaric chamber operating at a working pressure of 3 atmospheres. This chamber promises to transform HBOT treatment and its accessibility.

In an exclusive interview with Yoav Blat, BARIKS’ Representative in North America, we explore the technology behind this chamber and its potential to revolutionize and redefine the HBOT Landscape.

After an intensive four-year development, BARIKS is set to launch its state-of-the-art chambers in early 2024. Traditionally, Hyperbaric Oxygen Therapy (HBOT), known for its remarkable healing potential and diverse medical contexts, has been confined to specialized medical facilities.

Differing from traditional methods involving large multi-place chambers or less innovative monoplace chambers, BARIKS’ solution transcends the 2 ATA pressure barrier, enabling transformative treatments. Its applications span medical care, cognitive enhancement, sports medicine, anti-aging, and aesthetics while enhancing overall quality of life.

BARIKS’ achievement is poised to reshape HBOT, unlocking new dimensions of healing and wellness.

Our chamber design embodies innovation, folding into a suitcase within minutes, fitting into a car trunk, and weighing a mere 25 kilograms. This eliminates the necessity for hospital visits, making treatments convenient wherever you are.

Integrated software enhances our chamber, offering personalized treatments and precise data analysis to cater to individual preferences and meet stringent medical monitoring standards.

BARIKS’ commitment to pioneering technology propels the future of hyperbaric therapy, ensuring accessibility and efficacy for all by democratizing access to this transformative therapy.

Patents and Grants

Our technologies are fortified by patents, including co-invention of chamber body material with an Israeli specialist factory exclusively owned by Bariks.

Our software platform features robust security mechanisms and a patented distinct approach to HBOT.

Bariks secured a substantial grant from the Israel Innovation Authority.  $1 million annually for three years. This underscores our technological potential and exceptional team. The Authority’s stringent due diligence process sets a high standard for investors and collaborators.

The Visionary Team Driving BARIKS’ Innovation

Admiral Yedidya Ya‘ari – Co-Chairman, Former CEO of Rafael Advanced Defense Systems, and commander of the Israeli Navy

Boaz Misholi – Co-Chairman Tech entrepreneur with a legacy of success,

Dr. Yehuda Melamed – Medical Director, Pioneering hyperbaric medicine expert

Amir Shukrun – CEO, Vast experience in private equity and management.

A Vision for the Future

The BARIKS Team, armed with extensive expertise, spearheads the HBOT revolution.

The company’s financial projections indicate a promising future, with robust growth anticipated. Sales are projected to reach hundreds of millions over the next few years, propelling BARIKS to a substantial valuation. This will be supported by a strong balance sheet and successful operations, crucial in today’s valuation landscape.

BARIKS is ready to usher in a transformative era in Hyperbaric Oxygen Therapy, positioning itself as a pioneering innovator and introducing accessible and effective treatment options for all.

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.